Related Experiment Video
Updated: Nov 4, 2025

Mucin Agarose Gel Electrophoresis: Western Blotting for High-molecular-weight Glycoproteins
Published on: June 14, 2016
A few challenges in mucopolysaccharidosis type I
Luisa Bay1, Hernán Amartino2, Alejandra Antacle3
1Servicio de Errores Congénitos del Metabolismo, Hospital "Prof. Dr. Juan P. Garrahan". bay.luisa@gmail.com.
Mucopolysaccharidosis type I (MPS I) presents challenges in classification, early diagnosis, and managing specific disease manifestations. Addressing these is crucial for effective treatment and patient care transitions.
Area of Science:
- Biomedical research
- Rare diseases
- Metabolic disorders
Background:
- Mucopolysaccharidosis type I (MPS I) is a rare genetic disorder with significant clinical heterogeneity.
- Current management strategies face several unresolved challenges impacting patient outcomes.
Purpose of the Study:
- To outline the key challenges in the diagnosis and management of MPS I.
- To discuss the implications for therapeutic indications and patient care pathways.
Main Methods:
- Review of current literature and clinical practice guidelines for MPS I.
- Analysis of diagnostic criteria, treatment protocols, and patient care transitions.
Main Results:
- Inadequate classification systems hinder precise therapeutic indication.
- Early diagnosis via neonatal screening faces implementation barriers.
- Management of spinal and ocular disease requires standardized protocols.
- Allergic reactions to enzyme replacement therapy necessitate careful monitoring and treatment.
- Transitioning care from pediatric to adult services is complex.
Conclusions:
- Standardized classification and early diagnosis are vital for optimal MPS I management.
- Comprehensive care plans addressing specific disease manifestations and treatment side effects are essential.
- Improved transition strategies are needed for long-term adult patient care.
More Related Videos
08:51Profiling of Permethylated Mucin O-glycans Using Matrix-assisted Laser Desorption/Ionization Time-of-flight Mass Spectrometry
Published on: June 20, 2025
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Related Concept Videos
Lysosomal Hydrolases
Proteoglycans
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...